123 related articles for article (PubMed ID: 23446822)
1. Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial.
Nishimura R; Anan K; Yamamoto Y; Higaki K; Tanaka M; Shibuta K; Sagara Y; Ohno S; Tsuyuki S; Mase T; Teramukai S
Oncol Rep; 2013 May; 29(5):1707-13. PubMed ID: 23446822
[TBL] [Abstract][Full Text] [Related]
2. Ribociclib plus Endocrine Therapy in Early Breast Cancer.
Slamon D; Lipatov O; Nowecki Z; McAndrew N; Kukielka-Budny B; Stroyakovskiy D; Yardley DA; Huang CS; Fasching PA; Crown J; Bardia A; Chia S; Im SA; Ruiz-Borrego M; Loi S; Xu B; Hurvitz S; Barrios C; Untch M; Moroose R; Visco F; Afenjar K; Fresco R; Severin I; Ji Y; Ghaznawi F; Li Z; Zarate JP; Chakravartty A; Taran T; Hortobagyi G
N Engl J Med; 2024 Mar; 390(12):1080-1091. PubMed ID: 38507751
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903).
Edmondson RJ; O'Connell RL; Banerjee S; Mileshkin L; Sykes P; Beale P; Fisher A; Bonaventura A; Millan D; Nottley S; Benson C; Hamilton A; Sjoquist K; Alexander L; Kelly C; Carty K; Divers L; Bradshaw N; Friedlander M;
Gynecol Oncol; 2021 Dec; 163(3):524-530. PubMed ID: 34625284
[TBL] [Abstract][Full Text] [Related]
4. Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.
Arnedos M; Drury S; Afentakis M; A'Hern R; Hills M; Salter J; Smith IE; Reis-Filho JS; Dowsett M
Ann Oncol; 2014 Mar; 25(3):605-610. PubMed ID: 24525703
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study.
Afentakis M; Dowsett M; Sestak I; Salter J; Howell T; Buzdar A; Forbes J; Cuzick J
Breast Cancer Res Treat; 2013 Jul; 140(2):253-62. PubMed ID: 23852223
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of anastrozole in patients with estrogen receptor/progesterone receptor positive recurrent low-grade endometrial stromal sarcomas: The PARAGON trial (ANZGOG 0903).
Friedlander M; Benson C; O'Connell RL; Reed N; Clamp A; Lord R; Millan D; Nottley S; Amant F; Steer C; Anand A; Mileshkin L; Beale P; Banerjee S; Bradshaw N; Kelly C; Carty K; Divers L; Alexander L; Edmondson R
Gynecol Oncol; 2021 Apr; 161(1):160-165. PubMed ID: 33608144
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer.
Robertson JF; Dixon JM; Sibbering DM; Jahan A; Ellis IO; Channon E; Hyman-Taylor P; Nicholson RI; Gee JM
Breast Cancer Res; 2013 Mar; 15(2):R18. PubMed ID: 23497452
[TBL] [Abstract][Full Text] [Related]
8. POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients.
Baird RD; van Rossum AGJ; Oliveira M; Beelen K; Gao M; Schrier M; Mandjes IAM; Garcia-Corbacho J; Vallier AL; Dougall G; van Werkhoven E; Linossi C; Kumar S; van Tinteren H; Callari M; Beddowes E; Perez-Garcia JM; Rosing H; Platte E; Nederlof P; Schot M; de Vries Schultink A; Bernards R; Saura C; Gallagher W; Cortès J; Caldas C; Linn SC
Clin Cancer Res; 2019 Nov; 25(22):6598-6605. PubMed ID: 31439579
[TBL] [Abstract][Full Text] [Related]
9. Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor-Positive/Androgen Receptor-Positive Advanced Breast Cancer.
Lu Q; Xia W; Lee K; Zhang J; Yuan H; Yuan Z; Shi Y; Wang S; Xu F
Oncologist; 2020 Jan; 25(1):21-e15. PubMed ID: 31434793
[TBL] [Abstract][Full Text] [Related]
10. Multiple gene aberrations and breast cancer: lessons from super-responders.
Wheler JJ; Atkins JT; Janku F; Moulder SL; Yelensky R; Stephens PJ; Kurzrock R
BMC Cancer; 2015 May; 15():442. PubMed ID: 26021831
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial.
Iwata H; Nakamura R; Masuda N; Yamashita T; Yamamoto Y; Kobayashi K; Tsurutani J; Iwasa T; Yonemori K; Tamura K; Aruga T; Tokunaga E; Kaneko K; Lee MJ; Yuno A; Kawabata A; Seike T; Kaneda A; Nishimura Y; Trepel JB; Saji S
Jpn J Clin Oncol; 2023 Jan; 53(1):4-15. PubMed ID: 36398439
[TBL] [Abstract][Full Text] [Related]
12. Survival outcome of combined GnRH agonist and tamoxifen is comparable to that of sequential adriamycin and cyclophosphamide chemotherapy plus tamoxifen in premenopausal patients with early breast cancer.
Sa-Nguanraksa D; Krisorakun T; Pongthong W; O-Charoenrat P
Mol Clin Oncol; 2019 Nov; 11(5):517-522. PubMed ID: 31620283
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903.
Mileshkin L; Edmondson R; O'Connell RL; Sjoquist KM; Andrews J; Jyothirmayi R; Beale P; Bonaventura T; Goh J; Hall M; Clamp A; Green J; Lord R; Amant F; Alexander L; Carty K; Paul J; Scurry J; Millan D; Nottley S; Friedlander M;
Gynecol Oncol; 2019 Jul; 154(1):29-37. PubMed ID: 31130288
[TBL] [Abstract][Full Text] [Related]
14. RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer.
Howell A; Ashcroft L; Fallowfield L; Eccles DM; Eeles RA; Ward A; Brentnall AR; Dowsett M; Cuzick JM; Greenhalgh R; Boggis C; Motion J; Sergeant JC; Adams J; Evans DG
Cancer Epidemiol Biomarkers Prev; 2018 Jan; 27(1):58-66. PubMed ID: 29097444
[No Abstract] [Full Text] [Related]
15. Real-World Patient Characteristics, Treatment Patterns, and Outcomes of HR+, HER2- Early Breast Cancer Patients in Japan: An Analysis with National Database(NDB).
Komatsu S; Kawai M; Takada M; Nakayama T; Masuda N; Shiheido H; Cai Z; Huang YJ; Kawaguchi T; Tanizawa Y
Gan To Kagaku Ryoho; 2023 Dec; 50(12):1283-1294. PubMed ID: 38247066
[TBL] [Abstract][Full Text] [Related]
16. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study.
Taylor CW; Green S; Dalton WS; Martino S; Rector D; Ingle JN; Robert NJ; Budd GT; Paradelo JC; Natale RB; Bearden JD; Mailliard JA; Osborne CK
J Clin Oncol; 1998 Mar; 16(3):994-9. PubMed ID: 9508182
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of combined therapy of goserelin and letrozole on very young women with advanced breast cancer as first-line endocrine therapy.
Liu X; Qu H; Cao W; Wang Y; Ma Z; Li F; Wang H
Endocr J; 2013; 60(6):819-28. PubMed ID: 23714650
[TBL] [Abstract][Full Text] [Related]
18. Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer.
Noguchi S; Kim HJ; Jesena A; Parmar V; Sato N; Wang HC; Lokejaroenlarb S; Isidro J; Kim KS; Itoh Y; Shin E
Breast Cancer; 2016 Sep; 23(5):771-9. PubMed ID: 26350351
[TBL] [Abstract][Full Text] [Related]
19. Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer.
Wang J; Xu B; Yuan P; Ma F; Li Q; Zhang P; Cai R; Fan Y; Luo Y; Li Q
Medicine (Baltimore); 2015 Jul; 94(26):e1006. PubMed ID: 26131799
[TBL] [Abstract][Full Text] [Related]
20. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
Robertson JFR; Bondarenko IM; Trishkina E; Dvorkin M; Panasci L; Manikhas A; Shparyk Y; Cardona-Huerta S; Cheung KL; Philco-Salas MJ; Ruiz-Borrego M; Shao Z; Noguchi S; Rowbottom J; Stuart M; Grinsted LM; Fazal M; Ellis MJ
Lancet; 2016 Dec; 388(10063):2997-3005. PubMed ID: 27908454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
